---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-002294"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:47:13.551265+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Adamis extension to June 26, 2023 to meet $1 bid price; reverse split required if needed

## Summary
- Nasdaq Hearings Panel granted extension through June 26, 2023 to evidence compliance with $1.00 bid price rule.
- Conditions include seeking shareholder approval for reverse stock split and effecting it if needed to achieve $1.00 bid for 10 consecutive days.
- Company previously failed to comply by Dec 27, 2022 after two 180-day grace periods.
- CEO mentions strategic and financing alternatives process announced in October 2022.

## SEC filing metadata
- accession: 0001387131-23-002294
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/0001387131-23-002294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/admp-8k_022123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-002294
- JSON: https://secwatch.observer/filing/0001387131-23-002294.json
- Plain text: https://secwatch.observer/filing/0001387131-23-002294.txt

## Key facts
- Listing & Compliance Notices
  DMK PHARMACEUTICALS Corp received a nasdaq hearing update notice regarding minimum bid price (rules 5500(a)(2)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: minimum bid price
  - Rules: 5500(a)(2)
  source text: February 21, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) had granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to the Company evidencing compliance with all applicable criteria for continued listing, including the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5500(a)(2) (the “Rule”), by no later than June 26, 2023 (the “Compliance Period”). The Company’s continued listing is subject to the Comp
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123002294/0001387131-23-002294-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.